Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Arts
  • Non-profit
  • Technology
  • Education
  • Books
ncarol.com

Cure SMA Announces New Funding For Network Of Prominent SMA Clinical Research And Treatment Centers
ncarol.com/10061367

Trending...
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
Cure SMA
The Pediatric Neuromuscular Clinical Research Network Will Continue to Drive Treatment Development Under Cure SMA's Funding

CHICAGO - ncarol.com -- In the midst of the ongoing Coronavirus (COVID-19) global pandemic, Cure SMA is pleased to announce its new funding for the Pediatric Neuromuscular Clinical Research Network (PNCRN). In 2020, Cure SMA will provide $1.2 million to this Network of highly skilled clinical trial investigators, clinical evaluators, clinical coordinators, statisticians, and data management personnel.

In recent years, there have been many important medical breakthroughs, offering new and effective SMA treatment options. The PNCRN has been involved in the seminal clinical trials that have led to the FDA approvals of anti-sense oligonucleotides, gene transfer strategies, and other breakthrough treatments that have changed forever the natural course of the disease. Their work continues to develop and refine more sensitive outcome measures, conduct ongoing clinical trials, accelerate newborn screening programs, and identify promising new treatment approaches.

"In these unprecedented times, we see the investment in the PNCRN as critical in our mission to advance treatment and care," says Kenneth Hobby, President, Cure SMA, the leading national organization dedicated to finding effective treatments, care protocols and, ultimately, a cure for SMA. "We are eager to build on the past accomplishments of the Network, made possible by the generous and continuous sponsorship from the SMA Foundation."

Originally funded by the SMA Foundation in 2004, the PNCRN established a team of SMA clinical trial experts that have integrated clinical research, education, and care to achieve the best possible clinical trial outcomes. Cure SMA has collaborated with the SMA Foundation as co-sponsor of the PNCRN since 2018.

"The SMA Foundation has built and supported this Network for the past 15 years to establish a group of multidisciplinary SMA expert centers that support clinical trials," said Loren A. Eng, President, SMA Foundation. "Through the PNCRN, the Foundation has supported key clinical research studies, such as the SMA Natural History Study and the development of key SMA outcome measures that currently are accepted and used globally. The Natural History of SMA in the modern era was clearly defined by the Network and has been used as a key benchmark to assess safety and effectiveness of potential therapies, and ultimately to obtain recent treatment approvals."

More on ncarol.com
  • Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
  • Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
  • Lamaze International and Plumtree Baby Launch New Childbirth Education Materials
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care

"Since the advent of effective SMA treatments, the recognition and description of new SMA phenotypes in treated patients and the durability of the approved treatments have emerged as critical issues, making the continuing work to understand the disease mechanisms and phenotype-genotype correlations that much more important," says Darryl De Vivo, M.D., Director of the PNCRN and Professor of Neurology and Pediatrics, Columbia University Irving Medical Center, New York City. "Cure SMA's leadership in SMA research, and its new support of the PNCRN, will allow us to sustain this ground-breaking collaboration in SMA research and clinical care, especially as we expand the number of effective treatments for SMA and pursue the ultimate vision of a cure."

Six sites comprise the PNCRN for SMA, including Boston Children's Hospital, Boston, MA; Children's Hospital of Philadelphia, Philadelphia, PA; Columbia University Irving Medical Center, New York, NY; Nemours Children's Health System, Orlando FL; Stanford University, Palo Alto, CA; and the data coordinating center at the University of Rochester, Rochester, NY.

These clinical research and treatment sites have also now been integrated into the established Cure SMA Care Center Network, which will lead to real-world evidence that increases access to approved treatments and improves care for individuals and families with SMA.

About SMA

Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease that robs an individual of their ability to walk, swallow, and—in the most severe cases—even breathe. SMA is the leading genetic cause of death for infants. Symptoms can surface within the first 6 months of life (Type 1, the most severe and common), during the toddler years (Types 2 and 3), or in adulthood (Type 4, the least common form). SMA affects 1 in 11,000 births in the United States each year, and approximately 1 in 50 Americans is a genetic carrier. The good news is that there are now truly effective FDA-approved treatments for SMA that make it possible for individuals with SMA to achieve developmental milestones and live full and productive lives.

More on ncarol.com
  • Walnut Hills Launches Off-Grid Hempcrete Homes and Eco-Retreat in Western NC
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side

About Cure SMA

Cure SMA is dedicated to the treatment and cure of spinal muscular atrophy (SMA). Since 1984, Cure SMA has grown to be the largest network of individuals, families, clinicians, and research scientists working together to advance SMA research, support affected individuals/caregivers, and educate public and professional communities about SMA. The organization has directed and invested in comprehensive research that has shaped the scientific community's understanding of SMA, led to breakthroughs in treatment and care, and provided individuals and families the support they need today. For more information, visit www.cureSMA.org.

About SMA Foundation

Founded in 2003, the SMA Foundation is a nonprofit organization dedicated to accelerating the development of treatments for SMA through targeted funding of clinical research and novel drug development efforts. Since its inception, the Foundation has awarded ~$150 million for SMA research. In addition, the Foundation is committed to raising awareness and generating support for increased research efforts in SMA among the leaders of industry and government. When the SMA Foundation was founded, there were no treatments for SMA available. Today there are two approved treatments and several more in clinical and preclinical development. For more information, visit the SMA Foundation website at http://www.smafoundation.org.

Contact
Leslie Humbel
***@curesma.org


Source: Cure SMA
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
  • Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
  • Community-Based Marriage Enrichment Support
  • Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Scott Burton Releases Chaos: The Weight of a Memory, a Poetic Journey Through What Still Lingers
  • The Business Hyve Opens Waitlist for Groundbreaking Community Built for Small Business Success
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
_catLbl0 _catLbl1

Popular on ncarol.com

  • Real Estate CEO Launches Explosive New Book After $275,784 Wire Fraud Incident - 109
  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 106
  • JMC Princess Announces Release of Empowering New Single "PRETTY" – A Summer Anthem for Young Girls Everywhere
  • RemoteSEO Launches Targeted Digital Marketing for RTP Businesses
  • Let's Talk Series: At the Crossroads: Immigration Today
  • csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
  • Mauro Schnaidman named as Managing Director in Miami, Florida
  • Manhattan Boutique Real Estate Collaborates with InterContinental Hotels NYC in a Branding Partners Personalized Approach
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth

Similar on ncarol.com

  • Why Regular Visits to a Dentist in Kernersville Protect More Than Just Your Smile
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
  • Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute